Tags

Type your tag names separated by a space and hit enter

Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
Leuk Lymphoma 2019; :1-4LL

Authors+Show Affiliations

a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland. b Internal Medicine and Clinical Hematology Department, Kasr Alainy Faculty of Medicine, Cairo University , Giza , Egypt.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.a Department of Haematology, University Hospitals Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31402762

Citation

McIlroy, Graham, et al. "Mixed T-cell Chimerism at 3 Months Followed By Donor Lymphocyte Infusion Is Independently Associated With Favorable Outcomes in Alemtuzumab-based Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation." Leukemia & Lymphoma, 2019, pp. 1-4.
McIlroy G, Nikolousis E, Abou-Zeid N, et al. Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2019.
McIlroy, G., Nikolousis, E., Abou-Zeid, N., Shankara, P., Kishore, B., Kaparou, M., ... Kanellopoulos, A. (2019). Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation. Leukemia & Lymphoma, pp. 1-4. doi:10.1080/10428194.2019.1650177.
McIlroy G, et al. Mixed T-cell Chimerism at 3 Months Followed By Donor Lymphocyte Infusion Is Independently Associated With Favorable Outcomes in Alemtuzumab-based Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation. Leuk Lymphoma. 2019 Aug 11;1-4. PubMed PMID: 31402762.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation. AU - McIlroy,Graham, AU - Nikolousis,Emmanouil, AU - Abou-Zeid,Nervana, AU - Shankara,Paneesha, AU - Kishore,Bhuvan, AU - Kaparou,Maria, AU - Lovell,Richard, AU - Elmoamly,Shereef, AU - Davies,David, AU - Horgan,Claire, AU - Shenouda,Amir, AU - Kanellopoulos,Alexandros, Y1 - 2019/08/11/ PY - 2019/8/13/entrez SP - 1 EP - 4 JF - Leukemia & lymphoma JO - Leuk. Lymphoma SN - 1029-2403 UR - https://www.unboundmedicine.com/medline/citation/31402762/Mixed_T-cell_chimerism_at_3_months_followed_by_donor_lymphocyte_infusion_is_independently_associated_with_favorable_outcomes_in_alemtuzumab-based_reduced-intensity_allogeneic_hematopoietic_stem_cell_transplantation L2 - http://www.tandfonline.com/doi/full/10.1080/10428194.2019.1650177 DB - PRIME DP - Unbound Medicine ER -